Laser versus sham for genitourinary syndrome of menopause: A randomised controlled trial
BJOG: An International Journal of Obstetrics & Gynaecology · 2023-02 · 130 (3) · 312-319
DOI: 10.1111/1471-0528.17335 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift BJOG: An International Journal of Obstetrics & Gynaecology, online erschienen am 15.11.2022. Verfasst von Ann-Sophie Page und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department Obstetrics and Gynaecology, Pelvic Floor Unit, University Hospitals KU Leuven, and Academic Department Development and Regeneration, Clust…. Hauptthemen laut MEDLINE: Vaginal Diseases, Lasers, Gas, Laser Therapy. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 35 Literaturangaben.
Abstract (Originalsprache)
Objective
To assess whether CO 2 laser treatment is more effective than sham application in relieving the most bothersome symptom (MBS) in women with genitourinary syndrome of menopause (GSM).
Design
Single‐centre, sham‐controlled, double‐blind, randomised trial.
Setting
A tertiary centre in Belgium. Population Sixty women with moderate to severe GSM symptoms.
Methods
All participants eventually received three consecutive laser and three consecutive sham applications, either first laser followed by sham, or conversely. Main outcome measures The primary outcome was the participant‐reported change in severity of the MBS at 12 weeks. Secondary outcomes included subjective (patient satisfaction, sexual function, urinary function) and objective (pH, Vaginal Health Index Score, in vivo microscopy) measurements assessing the short‐term effect and the longevity of treatment effects at 18 months after start of the therapy. Adverse events were reported at every visit.
Results
The MBS severity score decreased from 2.86 ± 0.35 to 2.17 ± 0.93 (−23.60%; 95% CI −36.10% to −11.10%) in women treated with laser compared with 2.90 ± 0.31 to 2.52 ± 0.78 (−13.20%; 95% CI −22.70% to −3.73%) in those receiving sham applications ( p = 0.13). There were no serious adverse events reported up to 18 months.
Conclusions
In women with GSM, the treatment response 12 weeks after laser application was comparable to that of sham applications. There were no obvious differences for secondary outcomes and no serious adverse events were reported.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department Obstetrics and Gynaecology, Pelvic Floor Unit, University Hospitals KU Leuven, and Academic Department Development and Regeneration, Cluster Urogenital Surgery, KU Leuven, Leuven, Belgium.
- Department of Public Health and Primary Care, KU Leuven, Leuven, Belgium.
- Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
- Department Obstetrics and Gynaecology, University Hospitals Leuven, and Academic Department Development and Regeneration, Cluster Urogenital Surgery, KU Leuven, Leuven, Belgium.
- Department of Obstetrics and Gynaecology, Amsterdam Reproduction & Development Research Institute, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
ORCID-Profile: Yani P Latul, Jan Deprest
Zitieren
APA
Page, A. S., Verbakel, J. Y., Verhaeghe, J., Latul, Y. P., Housmans, S., & Deprest, J. (2023). Laser versus sham for genitourinary syndrome of menopause: A randomised controlled trial. BJOG: An International Journal of Obstetrics & Gynaecology, 130(3), 312-319. https://doi.org/10.1111/1471-0528.17335
Vancouver
Page AS, Verbakel JY, Verhaeghe J, Latul YP, Housmans S, Deprest J. Laser versus sham for genitourinary syndrome of menopause: A randomised controlled trial. BJOG: An International Journal of Obstetrics & Gynaecology. 2023;130(3):312-319. doi:10.1111/1471-0528.17335
BibTeX
@article{Page2023,
author = {Page, Ann-Sophie and Verbakel, Jan Y and Verhaeghe, Johan and Latul, Yani P and Housmans, Susanne and Deprest, Jan},
title = {Laser versus sham for genitourinary syndrome of menopause: A randomised controlled trial},
journal = {BJOG: An International Journal of Obstetrics & Gynaecology},
year = {2023},
volume = {130},
number = {3},
pages = {312--319},
doi = {10.1111/1471-0528.17335}
}
EUVIMED